newsfilter
← Latest News
Business Wire·

Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® at American Society of Retina Specialists Meeting

IVERIC bio, Inc. (NASDAQ:ISEE) announced today that in a post-hoc analysis from the GATHER1 clinical trial, Zimura showed a reduction of geographic atrophy lesion growth, compared to sham, across all distances from the foveal center point. The analysis